Drug Profile

MDG 3010

Alternative Names: MDG-3010

Latest Information Update: 10 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MediGene AG; WuXi Biologics
Developer MediGene AG
Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Solid tumours

Most Recent Events

05 Dec 2024 Medigene has patent protection for 3S (sensitive, specific, and safe) TCRs and exclusive E2E Platform technologies in World
01 Oct 2024 Medigene AG plans proof of principle study for MDG 3010 by the end of 2025 (Medigene AG pipeline, October 2024)
25 Sep 2024 Early research in Solid tumours in Germany (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com